MX368485B - Bioconjugados no aglomerantes de compuestos mimeticos de amilina y polietilenglicol. - Google Patents

Bioconjugados no aglomerantes de compuestos mimeticos de amilina y polietilenglicol.

Info

Publication number
MX368485B
MX368485B MX2015017356A MX2015017356A MX368485B MX 368485 B MX368485 B MX 368485B MX 2015017356 A MX2015017356 A MX 2015017356A MX 2015017356 A MX2015017356 A MX 2015017356A MX 368485 B MX368485 B MX 368485B
Authority
MX
Mexico
Prior art keywords
amylin
polyethyleneglycol
mimetic compounds
agglomerating bioconjugates
bioconjugates
Prior art date
Application number
MX2015017356A
Other languages
English (en)
Other versions
MX2015017356A (es
Inventor
Fernandes De Avila Netto Guterres Mariana
Mauricio Trambaioli Da Rocha E Lima Luis
Henrique Guerreiro Rosado Luiz
Melo Vieira Gonçalves Ferreira Bruno
Original Assignee
Univ Rio De Janeiro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rio De Janeiro filed Critical Univ Rio De Janeiro
Publication of MX2015017356A publication Critical patent/MX2015017356A/es
Publication of MX368485B publication Critical patent/MX368485B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

La presente invención se refiere en general a nuevos bioconjugados no aglomerantes de los compuestos mimétricos de amilina con polietilen glicol, y a su uso principalmente en el tratamiento de las enfermedades asociadas con la deposición o acumulación del amiloide extracelular que contribuye a la disfunción o insufiencia de los órganos sistémicos tales como el páncreas.
MX2015017356A 2013-06-14 2014-06-13 Bioconjugados no aglomerantes de compuestos mimeticos de amilina y polietilenglicol. MX368485B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRBR102013017626-5A BR102013017626A2 (pt) 2013-06-14 2013-06-14 Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças.
PCT/BR2014/000199 WO2014197961A1 (en) 2013-06-14 2014-06-13 Non-agglomerating bioconjugates of amylin-mimetic compounds and polyethyleneglycol

Publications (2)

Publication Number Publication Date
MX2015017356A MX2015017356A (es) 2016-12-20
MX368485B true MX368485B (es) 2019-10-04

Family

ID=52021510

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015017356A MX368485B (es) 2013-06-14 2014-06-13 Bioconjugados no aglomerantes de compuestos mimeticos de amilina y polietilenglicol.

Country Status (13)

Country Link
US (2) US20160331811A1 (es)
EP (1) EP3007721B1 (es)
JP (1) JP2016526533A (es)
CN (1) CN105658234A (es)
AU (1) AU2014280869B2 (es)
BR (1) BR102013017626A2 (es)
CA (1) CA2915104A1 (es)
ES (1) ES2720274T3 (es)
MX (1) MX368485B (es)
PL (1) PL3007721T3 (es)
PT (1) PT3007721T (es)
TR (1) TR201906773T4 (es)
WO (1) WO2014197961A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102015031283A2 (pt) * 2015-12-14 2018-09-18 Univ Rio De Janeiro Bioconjugado de amilina humana ou de análogos de amilinanão agregantes, composição, métodos para a preparação deuma composição, para o tratamento de uma doença oucondição e para estabilizar um composto amilino-mimético, e,medicamento
US10609584B2 (en) * 2016-08-12 2020-03-31 Telefonaktiebolaget Lm Ericsson (Publ) Selection of a carrier in multi-carrier operation system

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US7101853B2 (en) * 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
EP1474164B1 (en) * 2002-01-08 2008-10-29 Amylin Pharmaceuticals, Inc. Use of amylin, amylin analogs and amylin derivatives to treat dyslipidemia and triglyceridemia
JP2006506386A (ja) * 2002-10-22 2006-02-23 ワラタ ファーマシューティカルズ， インコーポレイテッド 糖尿病の処置
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
WO2006083254A1 (en) * 2004-02-11 2006-08-10 Amylin Pharmaceuticals, Inc. Amylin family peptides and methods for making and using them
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
WO2006105527A2 (en) * 2005-03-31 2006-10-05 Amylin Pharmaceuticals, Inc. Amylin and amylin agonists for treating psychiatric diseases and disorders
US7341720B2 (en) * 2005-04-06 2008-03-11 Genzyme Corporation Targeting of glycoprotein therapeutics
WO2006111169A1 (en) * 2005-04-21 2006-10-26 Gastrotech Pharma A/S Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
CN101400698A (zh) * 2006-03-15 2009-04-01 诺沃-诺迪斯克有限公司 胰岛淀粉样多肽衍生物
EP2102355B1 (en) * 2006-12-14 2016-03-02 Bolder Biotechnology, Inc. Long acting proteins and peptides and methods of making and using the same
EP2036539A1 (en) * 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
EP2036923A1 (en) * 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
CA2723821C (en) * 2008-05-16 2017-05-02 Nektar Therapeutics Conjugates of a cholinesterase moiety and a polymer
NZ589847A (en) * 2008-06-17 2013-01-25 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
WO2010033207A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of therapeutic peptides
BRPI1003424A2 (pt) * 2010-09-08 2013-01-08 Univ Rio De Janeiro sistema polimÉtrico de confinamento de amilina humana e anÁlogos agonistas, processo e uso; processo de avaliaÇço funcional de amilina liberada
WO2012065086A1 (en) * 2010-11-12 2012-05-18 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
WO2012162547A2 (en) * 2011-05-25 2012-11-29 Amylin Pharmaceuticals, Inc. Long duration dual hormone conjugates
JP6040464B2 (ja) * 2011-07-08 2016-12-07 アエゲリオン・ファーマシューティカルズ・インコーポレイテッドＡｅｇｅｒｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
US20140249076A1 (en) * 2011-10-18 2014-09-04 Astrazeneca Pharmaceuticals Lp Amylin-calcitonin chimeric peptides conjugated to duration enhancing moieties
US9830621B2 (en) * 2013-03-14 2017-11-28 Vdopia Inc. Systems and methods for layering content

Also Published As

Publication number Publication date
WO2014197961A9 (en) 2016-01-28
EP3007721A4 (en) 2016-12-07
AU2014280869B2 (en) 2017-11-02
JP2016526533A (ja) 2016-09-05
CN105658234A (zh) 2016-06-08
EP3007721A1 (en) 2016-04-20
PL3007721T3 (pl) 2019-09-30
ES2720274T3 (es) 2019-07-19
US20160184401A1 (en) 2016-06-30
PT3007721T (pt) 2019-05-13
WO2014197961A1 (en) 2014-12-18
TR201906773T4 (tr) 2019-05-21
MX2015017356A (es) 2016-12-20
EP3007721B1 (en) 2019-02-27
CA2915104A1 (en) 2014-12-18
US20160331811A1 (en) 2016-11-17
BR102013017626A2 (pt) 2015-02-10
AU2014280869A1 (en) 2016-01-07

Similar Documents

Publication Publication Date Title
MX2018013141A (es) Neurotoxinas quimericas.
MX2017007392A (es) Tratamiento de convulsiones con fosfatasa alcalina recombinante.
NZ730865A (en) Peptides having anti-inflammatory properties
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
ECSP17018120A (es) Triazolopirazinonas como inhibidores de pde1
EA201790378A1 (ru) Заключенное в липосому аффинное лекарственное средство
MX2015017532A (es) Métodos para modular la actividad del regulador de transmembrana de fibrosis quística.
IN2014DN09098A (es)
PH12016501702B1 (en) Pyrazole amide derivative
MX2019004500A (es) Terapia de combinación para la inhibición de componente de complemeto (c3).
MX2017004473A (es) Formulaciones de betalactamasa y usos de las mismas.
IN2014DN05885A (es)
MX2022014634A (es) Metodos para la administracion linfatica de agentes activos.
UY34616A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
EA201890212A1 (ru) Новое применение сульфата декстрана
NZ730092A (en) Use of cysteamine in treating infections caused by yeasts/moulds
ECSP16061208A (es) Quinazolin-thf-aminas como inhibidores de pde1
PH12020550185A1 (en) Semaglutide in medical therapy
MX2016000448A (es) Péptidos y análogos peptídicos protectores de tejido para prevenir y tratar enfermedades y trastornos asociados con daño del tejido.
CL2018002638A1 (es) Ambrisentan para uso en el tratamiento de insuficiencia renal aguda
MX2015017356A (es) Bioconjugados no aglomerantes de compuestos mimeticos de amilina y polietilenglicol.
ECSP16071574A (es) Hexahidrofuropirroles como inhibidores de pde1
NZ711523A (en) Use of sedoheptulose for prevention or treatment of inflammation
MX2018007236A (es) Bioconjugados no aglomerantes de amilina y compuestos mimeticos de amilina, composiciones que comprenden los mismos, y fabricacion y uso de los mismos.
GT201600158A (es) Filtros para equipos de infusión

Legal Events

Date Code Title Description
FG Grant or registration